<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>2C-I - Complete Profile</title>
    <link rel="stylesheet" href="/style.css">
</head>

<body>
  <body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/" class="site-title">Dyo's Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/">Home</a>
          </li>
          <li>
            <a href="/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/about/">About</a>
          </li>
          <li>
            <a href="/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/psychedelics/">Psychedelics</a> ‚Üí <span>2C-I</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üîÆ 2C-I</h1>
        <h2 class="chemical-name">2,5-Dimethoxy-4-iodophenethylamine</h2>
        
        <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="2C-I" 
                data-category="Psychedelics" 
                data-chemical="2,5-Dimethoxy-4-iodophenethylamine">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <span class="name-tag chemical">2C-I</span>
            <span class="name-tag chemical">2CI</span>
            <span class="name-tag street">Smiles</span>
            <span class="name-tag street">I-Series</span>
            <span class="name-tag chemical">4-Iodo-2,5-dimethoxyphenethylamine</span>
            <span class="name-tag street">Infinity</span>
            <span class="name-tag street">Crystal</span>
            <span class="name-tag research">NBOMe precursor</span>
            <span class="name-tag chemical">DMPEA-I</span>
            <span class="name-tag street">Visual Storm</span>
            <span class="name-tag research">Phenethylamine</span>
            <span class="name-tag chemical">Iodinated 2C</span>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category psychedelic">Research Chemical</span>
          <span class="legal-status schedule-1">Schedule I</span>
          <span class="duration long">8-12 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/2c-i.jpg" alt="2C-I powder and molecular structure" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>2,5-Dimethoxy-4-iodophenethylamine</p>
            <small>Halogen-substituted phenethylamine</small>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure 2C-I (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White to off-white crystalline powder</li>
            <li><strong>Texture:</strong> Fine crystalline material, sometimes chunky</li>
            <li><strong>Taste:</strong> Intensely bitter, metallic, numbing</li>
            <li><strong>Solubility:</strong> Soluble in water and alcohol</li>
            <li><strong>Stability:</strong> Light-sensitive, degrades in UV exposure</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Common Forms</h4>
          <ul>
            <li><strong>Powder:</strong> Most common, often in small bags</li>
            <li><strong>Tablets:</strong> Less common, usually pressed pills</li>
            <li><strong>Capsules:</strong> Gelatin caps with powder</li>
            <li><strong>Liquid:</strong> Rare, dissolved in alcohol or PG</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Critical Adulterant Warnings</h4>
          <p><strong>NBOMe substitution:</strong> Extremely dangerous - 25I-NBOMe is deadly at 2C-I doses</p>
          <p><strong>DOI substitution:</strong> Much longer duration (12-30 hours), higher toxicity</p>
          <p><strong>Other 2C compounds:</strong> 2C-T-7, 2C-T-2 have different potencies and risks</p>
          <p><strong>Always test:</strong> Ehrlich, Marquis, and Froehde reagents essential</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">2-5mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">5-10mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">10-18mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">18-25mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">25mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Critical Dosage Information</h4>
        <ul>
          <li><strong>Research chemical:</strong> Limited human safety data - proceed with extreme caution</li>
          <li><strong>Steep dose curve:</strong> Small increases create disproportionately intense effects</li>
          <li><strong>Long duration:</strong> 8-12 hours - plan accordingly</li>
          <li><strong>Slow onset:</strong> 1-2 hours - don't redose early</li>
          <li><strong>Individual sensitivity:</strong> Start low - some are extremely sensitive</li>
          <li><strong>Body weight factor:</strong> Heavier individuals may need slightly higher doses</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Research Chemical Warning:</strong> 2C-I has limited safety research. NBOMe contamination is extremely dangerous - always test with multiple reagents.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-2:00</span>
          <span class="effect">Onset - stomach discomfort, first visual distortions</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+2:00-4:00</span>
          <span class="effect">Come-up - intensifying visuals, body load</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-8:00</span>
          <span class="effect">Peak - intense visual effects, ego dissolution possible</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+8:00-12:00</span>
          <span class="effect">Comedown - gradual return, lingering visuals</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+12:00-24:00</span>
          <span class="effect">After effects - mental fatigue, emotional processing</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Positive Effects</h4>
          <ul>
            <li>Intense, complex visual hallucinations</li>
            <li>Enhanced pattern recognition and geometric perception</li>
            <li>Synesthesia and sensory crossover</li>
            <li>Philosophical insights and introspection</li>
            <li>Enhanced appreciation for art and music</li>
            <li>Spiritual or mystical experiences</li>
            <li>Emotional breakthrough potential</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Negative Effects</h4>
          <ul>
            <li>Severe nausea and stomach discomfort</li>
            <li>Anxiety, panic, or overwhelming fear</li>
            <li>Thought loops and confusion</li>
            <li>Body tension and muscle discomfort</li>
            <li>Vasoconstriction and circulation issues</li>
            <li>Sleep disruption for 12-24 hours</li>
            <li>Potential for challenging psychological experiences</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>2C-I is a potent partial agonist at 5-HT2A receptors, the primary target responsible for its hallucinogenic effects. The iodine substitution at the 4-position significantly increases potency compared to unsubstituted phenethylamines. It also shows significant activity at 5-HT2C receptors and moderate activity at 5-HT2B receptors, contributing to its complex effect profile.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor">5-HT2A</span>
            <span class="activity">Partial Agonist</span>
            <span class="potency">High (Ki ~0.5nM)</span>
            <span class="effects">Primary hallucinogenic effects, visual distortions</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">5-HT2C</span>
            <span class="activity">Partial Agonist</span>
            <span class="potency">Moderate (Ki ~2nM)</span>
            <span class="effects">Appetite suppression, mood effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">5-HT2B</span>
            <span class="activity">Partial Agonist</span>
            <span class="potency">Moderate (Ki ~5nM)</span>
            <span class="effects">Cardiovascular effects, potential cardiac valve risk</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">Œ±1-Adrenergic</span>
            <span class="activity">Antagonist</span>
            <span class="potency">Moderate</span>
            <span class="effects">Vasodilation, blood pressure effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">D1/D2</span>
            <span class="activity">Weak Antagonist</span>
            <span class="potency">Low</span>
            <span class="effects">Minor motor and mood effects</span>
          </div>
        </div>

        <h4>Pharmacokinetics & Metabolism</h4>
        <div class="metabolism-details">
          <p><strong>Absorption:</strong> Well absorbed orally, peak plasma at 2-4 hours</p>
          <p><strong>Metabolism:</strong> Primarily O-demethylation and deamination pathways</p>
          <p><strong>Half-life:</strong> ~6-8 hours (estimated from duration)</p>
          <p><strong>Elimination:</strong> Hepatic metabolism, renal excretion of metabolites</p>
          <p><strong>Bioavailability:</strong> High oral bioavailability (~80-90%)</p>
          <p><strong>Protein binding:</strong> Unknown, likely moderate</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <div class="unique-properties">
          <p><strong>Halogen substitution:</strong> Iodine at 4-position dramatically increases 5-HT2A potency</p>
          <p><strong>Extended duration:</strong> Longer-lasting than many phenethylamines due to metabolic profile</p>
          <p><strong>Visual selectivity:</strong> Particularly strong visual effects relative to emotional/empathogenic effects</p>
          <p><strong>Cardiovascular activity:</strong> 5-HT2B activity may contribute to vasoconstriction</p>
          <p><strong>Research chemical status:</strong> Limited human pharmacological data available</p>
        </div>

        <h4>Neurotoxicity & Safety Concerns</h4>
        <ul>
          <li><strong>5-HT2B activation:</strong> Potential cardiac valve fibrosis risk with chronic use</li>
          <li><strong>Vasoconstriction:</strong> Risk of compromised circulation, especially peripherally</li>
          <li><strong>Unknown metabolites:</strong> Iodinated metabolites may have unknown toxicity</li>
          <li><strong>Limited research:</strong> Long-term effects and safety profile poorly understood</li>
          <li><strong>Seizure threshold:</strong> May lower seizure threshold in susceptible individuals</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>NBOMe contamination:</strong> Often sold as 2C-I - NBOMe is deadly at 2C-I doses</li>
            <li><strong>Always test:</strong> Multiple reagent tests essential before consumption</li>
            <li><strong>Research chemical:</strong> Limited human safety data - unknown long-term risks</li>
            <li><strong>Cardiac effects:</strong> Significant vasoconstriction and cardiovascular stress</li>
            <li><strong>Long duration:</strong> 8-12 hours - ensure safe environment and time commitment</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Precautions</h4>
          <ul>
            <li><strong>Start very low:</strong> Begin with 5mg or less to assess sensitivity</li>
            <li><strong>Set and setting:</strong> Comfortable, safe environment with trusted person</li>
            <li><strong>No driving:</strong> Impairment lasts 12+ hours</li>
            <li><strong>Hydration:</strong> Maintain fluid intake, monitor body temperature</li>
            <li><strong>Medical conditions:</strong> Avoid with heart problems, mental health issues</li>
            <li><strong>Frequency limits:</strong> Wait at least 2 weeks between uses</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Cardiovascular disease, hypertension, seizure disorders, psychiatric conditions, family history of psychosis, or are taking psychiatric medications (especially MAOIs or lithium).</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous</h4>
          <ul>
            <li><strong>MAOIs:</strong> Risk of serotonin syndrome and hypertensive crisis</li>
            <li><strong>Tramadol:</strong> Serotonin syndrome and seizure risk</li>
            <li><strong>Lithium:</strong> Dramatically increased seizure risk</li>
            <li><strong>Stimulants:</strong> Dangerous cardiovascular strain and overheating</li>
            <li><strong>2C-T compounds:</strong> Unpredictable interactions and toxicity</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Risky</h4>
          <ul>
            <li><strong>Cannabis:</strong> May trigger anxiety or paranoia</li>
            <li><strong>Alcohol:</strong> Impairs judgment, increases dehydration risk</li>
            <li><strong>Benzodiazepines:</strong> May blunt effects but useful for emergencies</li>
            <li><strong>SSRIs:</strong> Reduced psychedelic effects, potential serotonin issues</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Caution</h4>
          <ul>
            <li><strong>Tryptamines:</strong> Additive effects, start with reduced doses</li>
            <li><strong>Other psychedelics:</strong> Cross-tolerance and enhanced effects</li>
            <li><strong>Nitrous oxide:</strong> Enhanced effects but short-lived</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <strong>United States:</strong> Schedule I controlled substance
          </div>
          <div class="jurisdiction">
            <strong>United Kingdom:</strong> Class A drug under Misuse of Drugs Act
          </div>
          <div class="jurisdiction">
            <strong>Canada:</strong> Schedule I controlled substance
          </div>
          <div class="jurisdiction">
            <strong>Australia:</strong> Schedule 9 prohibited substance
          </div>
          <div class="jurisdiction">
            <strong>Germany:</strong> Controlled under NpSG (New Psychoactive Substances Act)
          </div>
          <div class="jurisdiction">
            <strong>Netherlands:</strong> List I controlled substance
          </div>
        </div>
        
        <div class="therapeutic-status">
          <h4>üè• Research Status</h4>
          <p>2C-I has no approved medical uses and is not currently being researched for therapeutic applications. All use remains illegal and unregulated. Research is limited to basic pharmacological studies in laboratory settings.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1975</span>
          <p>First synthesized by Alexander Shulgin as part of 2C series exploration</p>
        </div>
        <div class="history-event">
          <span class="year">1991</span>
          <p>Detailed in PiHKAL as entry #34 with human bioassay data</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>Begins appearing in underground research chemical markets</p>
        </div>
        <div class="history-event">
          <span class="year">2003</span>
          <p>DEA emergency scheduling as Schedule I substance</p>
        </div>
        <div class="history-event">
          <span class="year">2010s</span>
          <p>Often mis-sold as NBOMe compounds or other substituted phenethylamines</p>
        </div>
        <div class="history-event">
          <span class="year">Present</span>
          <p>Remains available in research chemical markets despite legal restrictions</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Cultural Impact</h4>
        <p>2C-I represents part of the "2C family" that significantly influenced psychedelic research and underground culture. Alexander Shulgin's methodical exploration of substituted phenethylamines provided the foundation for understanding how small molecular changes create vastly different psychoactive effects. The compound remains popular among experienced psychedelic users seeking intense visual experiences, though its research chemical status and safety concerns limit mainstream adoption.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Basic Pharmacology</h4>
          <p>Limited research focuses on receptor binding profiles and basic pharmacokinetics. Most data comes from Shulgin's original work and limited animal studies.</p>
        </div>
        
        <div class="research-item">
          <h4>Safety Studies</h4>
          <p>Minimal safety research exists. Most safety information comes from user reports and emergency room presentations rather than controlled studies.</p>
        </div>
        
        <div class="research-item">
          <h4>Analytical Chemistry</h4>
          <p>Research focuses on detection methods for forensic analysis and drug testing, as well as distinguishing from dangerous adulterants like NBOMe compounds.</p>
        </div>
        
        <div class="research-item">
          <h4>Neuropharmacology</h4>
          <p>Limited studies on 5-HT receptor interactions and comparison with other phenethylamine psychedelics in laboratory settings.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Testing & Safety</h4>
        <ul>
          <li><a href="https://dancesafe.org">DanceSafe</a> - Reagent testing kits</li>
          <li><a href="https://www.ecstasydata.org">EcstasyData</a> - Professional testing service</li>
          <li><a href="https://energycontrol.org">Energy Control</a> - European testing services</li>
          <li><a href="https://www.theloop.org.uk">The Loop</a> - UK harm reduction testing</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Educational Resources</h4>
        <ul>
          <li><a href="https://erowid.org">Erowid</a> - Experience reports and information</li>
          <li><a href="https://psychonautwiki.org">PsychonautWiki</a> - Detailed pharmacological information</li>
          <li><a href="https://isomerdesign.com/PiHKAL">PiHKAL</a> - Original synthesis and bioassay data</li>
          <li><a href="https://www.bluelight.org">Bluelight</a> - Harm reduction forum discussions</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support & Emergency</h4>
        <ul>
          <li><a href="https://fireside.psych.org">Fireside Project</a> - Psychedelic crisis support</li>
          <li><a href="https://www.crisistextline.org">Crisis Text Line</a> - Text HOME to 741741</li>
          <li><a href="https://suicidepreventionlifeline.org">National Suicide Prevention Lifeline</a> - 988</li>
          <li><a href="https://www.poison.org">Poison Control</a> - 1-800-222-1222</li>
        </ul>
      </div>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/js/lunr.min.js"></script>
    <script src="/assets/js/search.js"></script>
    <script src="/assets/js/substance-integration.js"></script>
</body>
</html>